The Neuroprotective Effect of Losartan through Inhibiting AT1/ASK1/MKK4/JNK3 Pathway Following Cerebral I/R in Rat Hippocampal CA1 Region

It has been well documented that angiotensin II type 1 (AT1) receptor blockers (ARBs) are known to attenuate neural damage and the c‐Jun N‐terminal protein kinase 3 (JNK3) pathway and caspase‐3 signal are involved in neuronal cell death following cerebral ischemia/reperfusion (I/R). In this study, we first showed that losartan could protect neurons against cerebral I/R‐induced injury.

[1]  J. Brierley,et al.  A New Model of Bilateral Hemispheric Ischemia in the Unanesthetized Rat , 1979, Stroke.

[2]  R. Oppenheim,et al.  Role of programmed cell death in normal neuronal development and function , 2004, Anatomical science international.

[3]  R. Mullins,et al.  β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2 , 2000, The Journal of cell biology.

[4]  G. Steinberg,et al.  Cellular and molecular events underlying ischemia-induced neuronal apoptosis. , 2003, Drug news & perspectives.

[5]  G. Kim,et al.  Apoptosis signal-regulating kinase 1 (Ask1) targeted small interfering RNA on ischemic neuronal cell death , 2011, Brain Research.

[6]  M. Muda,et al.  Bcl-2 Undergoes Phosphorylation by c-Jun N-terminal Kinase/Stress-activated Protein Kinases in the Presence of the Constitutively Active GTP-binding Protein Rac1* , 1997, The Journal of Biological Chemistry.

[7]  Z. Gu,et al.  c-Jun N-terminal kinase activation in hippocampal CA1 region was involved in ischemic injury , 2001, Neuroreport.

[8]  R. Reiter,et al.  Melatonin inhibits neural apoptosis induced by homocysteine in hippocampus of rats via inhibition of cytochrome c translocation and caspase-3 activation and by regulating pro- and anti-apoptotic protein levels , 2005, Neuroscience.

[9]  E. Nishida,et al.  Molecular recognitions in the MAP kinase cascades. , 2003, Cellular signalling.

[10]  F. Cecconi,et al.  Expanding roles of programmed cell death in mammalian neurodevelopment. , 2005, Seminars in cell & developmental biology.

[11]  R. Lefkowitz,et al.  β-Arrestins and Cell Signaling , 2007 .

[12]  S. Nagahiro,et al.  Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: in-vivo and in-vitro studies , 2008, Journal of hypertension.

[13]  L. Rubin,et al.  The small GTP-binding protein Cdc42 is required for nerve growth factor withdrawal-induced neuronal death. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Ping Wang,et al.  Subcellular Localization of β-Arrestins Is Determined by Their Intact N Domain and the Nuclear Export Signal at the C Terminus* , 2003, The Journal of Biological Chemistry.

[15]  L. Bohn,et al.  Physiological and pharmacological implications of beta-arrestin regulation. , 2009, Pharmacology & therapeutics.

[16]  M. Mogi,et al.  Irbesartan attenuates ischemic brain damage by inhibition of MCP-1/CCR2 signaling pathway beyond AT₁ receptor blockade. , 2011, Biochemical and biophysical research communications.

[17]  H. Diener,et al.  The ACCESS Study: Evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors , 2003, Stroke.

[18]  Guang-yi Zhang,et al.  Blocking Daxx trafficking attenuates neuronal cell death following ischemia/reperfusion in rat hippocampus CA1 region. , 2011, Archives of biochemistry and biophysics.

[19]  D. Pei,et al.  Overexpression of the PDZ1 domain of PSD‐95 diminishes ischemic brain injury via inhibition of the GluR6·PSD‐95·MLK3 pathway , 2009, Journal of neuroscience research.

[20]  S. Benichou,et al.  Differential nucleocytoplasmic shuttling of beta-arrestins. Characterization of a leucine-rich nuclear export signal in beta-arrestin2. , 2002, The Journal of biological chemistry.

[21]  C. Sigmund,et al.  Ischemia-induced brain damage is enhanced in human renin and angiotensinogen double-transgenic mice. , 2009, American journal of physiology. Regulatory, integrative and comparative physiology.

[22]  Robert J. Lefkowitz,et al.  Identification of a Motif in the Carboxyl Terminus of β-Arrestin2 Responsible for Activation of JNK3* , 2001, The Journal of Biological Chemistry.

[23]  M. Kathmann,et al.  CB1 receptor density and CB1 receptor-mediated functional effects in rat hippocampus are decreased by an intracerebroventricularly administered antisense oligodeoxynucleotide , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.

[24]  Eric Reiter,et al.  GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. , 2006, Trends in endocrinology and metabolism: TEM.

[25]  Qun Chen,et al.  Cytoprotection by the modulation of mitochondrial electron transport chain: the emerging role of mitochondrial STAT3. , 2012, Mitochondrion.

[26]  L. Luttrell,et al.  Role of β-Arrestin-mediated Desensitization and Signaling in the Control of Angiotensin AT1a Receptor-stimulated Transcription* , 2008, Journal of Biological Chemistry.

[27]  R. Lefkowitz,et al.  Beta-arrestins and cell signaling. , 2007, Annual review of physiology.

[28]  Huiqing Liu,et al.  Losartan, an angiotensin II type 1 receptor blocker, ameliorates cerebral ischemia-reperfusion injury via PI3K/Akt-mediated eNOS phosphorylation , 2012, Brain Research Bulletin.

[29]  T. Herdegen,et al.  Blockade of central angiotensin AT(1) receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats. , 1999, Stroke.

[30]  R. Davis,et al.  Signal Transduction by the JNK Group of MAP Kinases , 2000, Cell.

[31]  A. Hofman,et al.  The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial , 2003, Journal of hypertension.

[32]  D. Choi.  Cerebral hypoxia: some new approaches and unanswered questions , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[33]  Eric Reiter,et al.  GRKs and β-arrestins: roles in receptor silencing, trafficking and signaling , 2006, Trends in Endocrinology & Metabolism.

[34]  A. Eshraghi,et al.  Arrest of Apoptosis in Auditory Neurons: Implications for Sensorineural Preservation in Cochlear Implantation , 2003, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.

[35]  Chun Guo,et al.  The β-Arrestin-2 Scaffold Protein Promotes c-Jun N-terminal Kinase-3 Activation by Binding to Its Nonconserved N Terminus* , 2008, Journal of Biological Chemistry.

[36]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[37]  S. Benichou,et al.  Differential Nucleocytoplasmic Shuttling of β-Arrestins , 2002, The Journal of Biological Chemistry.

[38]  Tian-Le Xu,et al.  Knock‐down of POSH expression is neuroprotective through down‐regulating activation of the MLK3–MKK4–JNK pathway following cerebral ischaemia in the rat hippocampal CA1 subfield , 2005, Journal of neurochemistry.